EUVIMEDObjevte EUVIMED
Systematische ÜbersichtMetaanalyseOpen access

Cancer cachexia reduces the efficacy of immune checkpoint inhibitors in cancer patients

Yean Yu, Li Yan, Tianhui Huang, Zhenfu Wu, Juan Liu

Aging · 2024-03-31 · 16 (6) · 5354-5369

DOI: 10.18632/aging.205652 ↗

At a glance

Systematische Übersicht in Aging, published online on 2024-03-11. Written by Yean Yu and 4 co-authors. Institution: Department of Nephrology, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan, China. Major MEDLINE topics: Cachexia, Immune Checkpoint Inhibitors, Neoplasms. Cited 16 times so far (Crossref); 49 references. The full text is freely available in PubMed Central.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

OBJECTIVE: Cachexia, a multifactorial syndrome, is frequently noticed in cancer patients. A recent study has shown inconsistent findings about the relationship between cachexia and the efficiency of immune checkpoint inhibitors (ICIs). To analyze this disparity, we did a meta-analysis. METHODS: From the beginning of each database to July 2023, literature describing the association between cachexia and prognosis of ICI-treated patients with solid malignancies was systematically searched in three online databases. Estimates were pooled, and 95% confidence intervals (CIs) were generated. RESULTS: We analyzed a total of 12 articles, which included data from 1407 patients. The combined results of our analysis showed that cancer patients with cachexia had significantly worse overall survival (HR = 1.88, 95% CI: 1.59-2.22, p < 0.001), progression-free survival (HR = 1.84, 95% CI: 1.59-2.12, p < 0.001), and time to treatment failure (HR = 2.15, 95% CI: 1.32-3.50, p = 0.002). These findings were consistent in both univariate and multivariate analyses. Additionally, while not statistically significant, we observed a trend towards a lower objective response rate in cancer patients with cachexia compared to those without cachexia (OR = 0.59, 95% CI: 0.32-1.09, p = 0.093). CONCLUSION: Poor survival in cachexia patients suggests a negative relationship between cachexia and ICI efficacy. In clinical practice, the existence of cachexia should be estimated to choose individuals who may benefit from ICIs.

Subjects

MeSH terms (MEDLINE)

CachexiaImmune Checkpoint InhibitorsNeoplasmsHumansTreatment OutcomePrognosisMale

Author keywords

cachexiacancersimmune checkpoint inhibitorsnon-small cell lung cancer

Substances

Immune Checkpoint Inhibitors

Authors and institutions

  • Department of Nephrology, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan, China.
  • Department of Traditional Chinese Medicine, Wuhan Third Hospital, Tongren Hospital of Wuhan University, Wuhan, China.
  • Department of Abdominal and Pelvic Medical Oncology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Huangshi, China.
  • Department of Critical Care Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, China.
  • Department of Critical Care Medicine, Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan, China.

Cite

APA

Yu, Y., Yan, L., Huang, T., Wu, Z., & Liu, J. (2024). Cancer cachexia reduces the efficacy of immune checkpoint inhibitors in cancer patients. Aging, 16(6), 5354-5369. https://doi.org/10.18632/aging.205652

Vancouver

Yu Y, Yan L, Huang T, Wu Z, Liu J. Cancer cachexia reduces the efficacy of immune checkpoint inhibitors in cancer patients. Aging. 2024;16(6):5354-5369. doi:10.18632/aging.205652

BibTeX
@article{Yu2024,
  author = {Yu, Yean and Yan, Li and Huang, Tianhui and Wu, Zhenfu and Liu, Juan},
  title = {Cancer cachexia reduces the efficacy of immune checkpoint inhibitors in cancer patients},
  journal = {Aging},
  year = {2024},
  volume = {16},
  number = {6},
  pages = {5354--5369},
  doi = {10.18632/aging.205652}
}
Start for free →